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According to the latest definition, the
term neuropathic pain refers to pain
arising as a direct consequence of a lesion
or disease affecting the somatosensory
system [1].
When physicians and researchers use
the term assessment of neuropathic pain,
they may be referring to two distinct types
of assessment: (1) assessing pain intensity
and quality and possibly their treatment-
induced changes, and (2) diagnosing
neuropathic (as opposed to non-neuro-
pathic) pain.
Pain is a complex experience that
depends strongly on cognitive, emotional,
and educational influences. Hence the
pressing need for tools that can measure
pain objectively. We distinguish four
different levels of ‘‘objectivity’’: (1) labora-
tory tests that use quantitative tools and
measure an objective response; (2) quan-
titative sensory testing, a measure that
despite using quantitative, graded stimuli
inevitably relies on the patient’s evalua-
tion; (3) bedside examination, which relies
on the physician’s experience and the
patient’s ability and willingness to collab-
orate; and (4) pain questionnaires, tools
that depend entirely on the patient. We
review each of these in turn, drawing in




(i.e., those that do not carry pain) have a
lower electrical threshold than small-size,
nociceptive afferents. Unless special tech-
niques are used, i.e., experimental blocks
or stimulation of special organs (cornea,
tooth pulp, glans), electrical stimuli un-
avoidably also excite large afferents, thus
hindering nociceptive signals. Hence stan-
dard neurophysiological responses to elec-
trical stimuli, such as nerve conduction
studies (NCS; see Glossary) and somato-
sensory-evoked potentials (SEPs), can
identify, locate, and quantify damage
along the peripheral or central sensory
pathways, but they do not assess nocicep-
tive pathway function [2,3].
For many years researchers have tried
numerous techniques for selectively acti-
vating pain afferents. The currently pre-
ferred approach uses laser stimulators to
deliver radiant-heat pulses that selectively
excite the free nerve endings (Ad and C) in
the superficial skin layers. Consensus from
over 200 studies now confirms that late
laser-evoked potentials (Ad-LEPs) are no-
ciceptive responses. Late LEPs are the
easiest and most reliable neurophysiolog-
ical tools for assessing nociceptive pathway
function and are diagnostically useful in
peripheral and central neuropathic pain
[4,5]. In clinical practice, their main
limitation is that they are currently
available in too few centres [2,3]. Ultra-
late LEPs (related to C-fibre activation) are
technically more difficult to record, and
few studies have assessed their usefulness
in patients with neuropathic pain [6].
Contact heat-evoked potentials are a
recent development that still need clinical
validation [7].
Painful neuropathies typically and pref-
erentially involve small nerve fibres. Nerve
biopsy may be unrewarding in the early
detection of small-fibre neuropathy be-
cause small-fibre assessment is difficult and
requires electron microscopy. Punch skin
biopsy can quantify Ad and C nerve fibres
by measuring the density of intra-epider-
mal nerve fibres (IENF). IENF loss has
been shown in various neuropathies char-
acterized by small-fibre axonal loss. Punch
skin biopsy is easy to do, minimally
invasive, and optimal for follow-up. De-
spite these advantages, it is useless in
central pain and demyelinating neuropa-
thy, and is currently available only in few
research centres [8,9].
Quantitative Sensory Testing
Quantitative sensory testing (QST)
analyses perception in response to external
stimuli of controlled intensity (Table 1).
Detection and pain thresholds are deter-
mined by applying stimuli to the skin in an
ascending and descending order of mag-
nitude. Mechanical sensitivity for tactile
stimuli is measured with plastic filaments
that produce graded pressures, such as the
von Frey hairs, pinprick sensation with
weighted needles, and vibration sensitivity
with an electronic vibrameter. Thermal
perception and thermal pain are measured
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operates on the thermoelectric effect.
QST has been used for the early
diagnosis and follow-up of small-fibre
neuropathy that cannot be assessed by
standard NCS, and has proved useful in
the early diagnosis of diabetic neuropathy.
QST is also especially suitable for quan-
tifying mechanical and thermal allodynia
and hyperalgesia in painful neuropathic
syndromes, and has been used in pharma-
cological trials to assess treatment efficacy
on provoked pains [2].
QST abnormalities, however, cannot
provide conclusive evidence of neuropathic
pain, because QST shows changes also in
non-neuropathic pain states, such as rheu-
matoid arthritis and inflammatory arthro-
myalgias. QST is time-consuming and thus
difficult to use in clinical practice [2].
Bedside Examination
In patients with neuropathic pain, ab-
normal sensory findings should be neuro-
anatomically logical, compatible with a
definite lesion site. Location, quality, and
intensity of pain should be assessed. Proper
assessmentrequiresaclearunderstandingof
the possible types of negative (e.g., sensory
loss) and positive (e.g., pain and paresthe-
sias) symptoms and signs. Neuropathic pain
can be spontaneous (stimulus-independent
or spontaneous pain) or elicited by a
stimulus (stimulus-dependent or provoked
pain). Spontaneous pain is often described
as a constant burning sensation, but may
also be intermittent or paroxysmal, and
includes dysesthesias and paresthesias. Pro-
voked pains (hyperalgesiaand allodynia) are
elicitedbymechanical,thermal,orchemical
stimuli.
Neurological examination in suspected
neuropathic pain should include assess-
ment of motor, sensory, and autonomic
phenomena in order to identify all signs of
neurological dysfunction. Sensory disor-
ders should be recorded in detail, prefer-
ably on body sensory maps (neurologists
draw the territories where they found a
sensory disturbance on schematic charts of
the body front and back). Although
difficult for the non-specialist and time-
consuming for everybody, drawing the
sensory abnormality provides valuable
information. Tactile sense is best assessed
with a piece of cotton wool, pinprick sense
with a wooden cocktail stick, thermal sense
with warm and cold objects (e.g., metal
thermorollers), and vibration sense with a
128-Hz tuning fork (Table 1) [2].




Ab Touch Piece of cotton wool Von Frey filaments NCS, SEPs
Vibration Tuning fork (128 Hz) Vibrameter
a NCS, SEPs
Ad Pinprick, sharp pain Wooden cocktail stick Weighted needles LEPs, IENF
Cold Thermoroller Thermode
b None




aOr other device providing graded vibratory stimuli.




Six Key Papers in the Field
Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, et al.
(2008) Neuropathic pain: Redefinition and a grading system for clinical
and research purposes. Neurology 70: 1630–1635. [1] The new definition
of neuropathic pain and a proposed diagnostic flow-chart that helps to grade
neuropathic pain as unlikely, possible, probable, and definite.
Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, et al. (2007)
Using screening tools to identify neuropathic pain. Pain 127: 199–203.
[10] A review that brings together the main authors of all the modern screening
tools for neuropathic pain and provides a pros-and-cons analysis.
Chou R, Qaseem A, Snow V, Casey D, Cross JT Jr, et al. (2007) Diagnosis
and treatment of low back pain: A joint clinical practice guideline from
the American College of Physicians and the American Pain Society. Ann
Intern Med 147: 478–491. These guidelines, specifically devoted to low back
pain, face the problem of differentiating nociceptive and neuropathic pain
components and recommend adequate methods.
Rolke R, Baron R, Maier C, To ¨lle TR, Treede RD, et al. (2006) Quantitative
sensory testing in the German Research Network on Neuropathic Pain
(DFNS): Standardized protocol and reference values. Pain 123: 231–
243. Although taking 30 min only, this is the most thorough and best validated
QST protocol available.
Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, et al.
(2005) Core outcome measures for chronic pain clinical trials: IMMPACT
recommendations. Pain 113: 9–19. A comprehensive review and authorita-
tive consensus that may help the reader to understand the important differences
in assessing pain in clinical practice and in pharmacological trials.
Cruccu G, Anand P, Attal N, Garcia-Larrea L, Haanpa ¨a ¨ M, et al. (2004)
EFNS guidelines on neuropathic pain assessment. Eur J Neurol 11: 153–
162. [2] So far, these are the only existing guidelines for assessing neuropathic
pain. They range from bedside examination to the most advanced laboratory
tools.
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Over recent years, several screening
tools for distinguishing neuropathic from
nociceptive pain have been validated [10].
Some of them, i.e., the Neuropathic Pain
Questionnaire (NPQ) [11], ID Pain [12],
and PainDETECT [13], rely only on
interview questions. PainDETECT was
designed to detect neuropathic pain com-
ponents in patients with low back pain; it
has been validated in about 8,000 patients
with low back pain, and reaches about
80% sensitivity and specificity [13].
The Leeds Assessment of Neuropathic
Symptoms and Signs (LANSS) scale [14]
and Douleur Neuropathique en 4 Questions (DN4)
questionnaire [15] use both interview
questions and physical tests (pinprick and
tactile hypoesthesia, pain to light touch),
and achieve highersensitivity and specificity
than the screening tools that use only
interview questions. The higher diagnostic
accuracy achieved by the LANSS scale and
DN4 questionnaire is hardly surprising
given that their scores also reflect physical
tests, and emphasizes the importance of
clinical examination. Neither LANSS nor
DN4 have been specifically evaluated in
patients with low back pain, however.
Table 2 provides a schematic comparison
between all these tools.
A New Tool: The Standardized
Evaluation of Pain (StEP)
In a new study reported in this issue of
PLoS Medicine, Joachim Scholz and col-
leagues present a pain assessment tool
called StEP (Standardized Evaluation of
Pain) that combines six interview questions
and ten physical tests [16]. This novel tool
assesses pain-related symptoms and signs
and differentiates distinct pain phenotypes
reflecting different mechanisms. Besides
being diagnostically useful, a standardized
approach for differentiating pain pheno-
types independently from disease aetiology
supports a mechanism-based concept of
classifying and treating pain and thus
offers an opportunity to improve targeted
analgesic treatment [17,18].
Scholz and colleagues specifically eval-
uated the diagnostic usefulness of StEP in
patients with low back pain, the most
frequent (and often challenging) pain
condition. Low back pain may comprise
both nociceptive axial and neuropathic
radicular pain. In these patients, differen-
tiating between nociceptive and neuro-
pathic pain is clinically important because
these components require different pain
management strategies. The differentia-
tion is also very important for pharmaco-
logical trials. By standardizing the assess-
ment of pain-related symptoms and signs,
StEP achieves more than 90% sensitivity
and specificity in distinguishing neuro-
pathic from nociceptive pain in patients
Table 2. Modern screening tools.
Questionnaires ID Pain NPQ PainDETECT LANSS DN4 StEP
Symptoms reported
Ongoing pain 2
Pricking, tingling pins, needles (any dysesthesia) ++ + +++
Electric shocks or shooting ++ + ++
Hot or burning ++ + ++2
Numbness ++ + +
Pain evoked by light touching ++ + +
Painful cold or freezing pain ++ 2
Pain evoked by mild pressure +
Pain evoked by heat or cold +
Pain evoked by changes in weather +
Pain limited to joints 2
Itching +
Temporal patterns or temporal summation + 2
Radiation of pain +
Autonomic changes +
Physical examination




Abnormal response to blunt pressure (decreased or
evoked pain)
+
Decreased response to vibration +
Brush allodynia ++2
Raised soft touch threshold + 2
Raised pinprick threshold +++
Straight-leg-raising test +
Skin changes 2
The minus sign (2) indicates items that reduce the score.
doi:10.1371/journal.pmed.1000045.t002
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DN4).
The most discriminatory StEP indica-
tors for radicular pain are simple and
widely used physical tests such as the
straight-leg-raising test (Lase `gue’s sign), a
deficit in cold detection, and a reduced
response to pinprick. Although in clinical
practice the assessment of sensory abnor-
malities without graded stimuli increases
the variability of outcomes, the standard-
ized application used in StEP improves the
diagnostic yield of the straight-leg-raising
test and the assessment of sensory deficits,
thus suggesting that StEP may be partic-
ularly useful in pharmacological trials.
In StEP, unlike the other screening
tools and in contrast with commonly held
views on neuropathic pain, the descrip-
tors ‘‘burning pain’’ and ‘‘brush allody-
nia’’ reduce the score for diagnosing
neuropathic radicular pain (Table 2).
Except for PainDETECT, however, all
the other screening tools have been
validated in neurological diseases other
than spondylotic radiculopathy, a condi-
tion that has distinct clinical manifesta-
tions. Furthermore, no pathognomonic
sensory descriptor exists for neuropathic
pain [19]. About 50% of patients with
musculoskeletal pain report shooting pain
and tingling sensations [20], and 30% of
patients with non-neuropathic pain re-
port burning pain [15]. Hence interview
questions alone cannot replace clinical
examination.
Conclusion
Despite intensive investigations, the
cause of neuropathic pain often remains
unknown, and careful assessment is need-
ed before pain can be labelled idiopathic
or psychogenic. Pain assessment has ad-
vanced enormously over recent years. But
whereas the new laboratory tools help in
diagnosing neuropathic pain and quanti-
fying damage to the nociceptive pathways,
they measure neither pain intensity nor
response to treatment. As StEP shows, the
most convenient approach is still to
combine physical examination and pa-
tient’s report.
In patients with chronic pain, after years
of suffering and frustrated hopes, a
psychological component often predomi-
nates, making patients non-compliant with
new treatments. Ascertaining what is really
useful for them becomes at this stage an
almost impossible task. Hence we badly
need an objective measure of pain inten-
sity and response to treatment. The only
method that seems reasonably likely to
solve this problem is functional neuroim-
aging. Yet it will not do so today—only in
the future, once it succeeds in providing
reliable measures at the individual level
and becomes standardized and widely
accessible.
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